Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits

Experimental Lung Research

Volumn 36, Issue 10, 2010, Pages 573-592

  Duan, Shu ^a   Zhang, Yan ^a   Wu, Shang Jie ^a   Jiang, Ling Zhi ^a   Zhang, Jing ^a   Gan, Yan ^a   Chen, Ping ^a   Zhao, Shui Ping ^a   Li, Gui Yuan ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Alveolar macrophages; Atorvastatin; Hypercholesterolemia; Inflammation; Pulmonary vascular remodeling

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; LIPID BLOOD LEVEL; LUNG ALVEOLUS MACROPHAGE; LUNG ARTERY; LUNG INFILTRATE; LUNG LAVAGE; LUNG LESION; LUNG PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY VASCULAR DISEASE; RABBIT;

ANIMALS; BODY WEIGHT; BRONCHOALVEOLAR LAVAGE FLUID; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTERLEUKIN-6; LIPIDS; LUNG; LUNG DISEASES; MACROPHAGES, ALVEOLAR; MALE; NF-KAPPA B; PROLIFERATING CELL NUCLEAR ANTIGEN; PULMONARY ARTERY; PYRROLES; RABBITS; RANDOM ALLOCATION;

EID: 78149256328     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902141003739715     Document Type: Article

References (46)

1. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Nieman DC, Henson DA, Nehlsen-Cannarella SL, Ekkens M, Utter AC, Butterworth DE, Fagoaga OR: Influence of obesity on immune function. J Am Diet Assoc. 1999;99:294-299.
3. Fantuzzi G, Faggioni R: Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000;68:437-446.
4. Johnston RA, Schwartzmun IN, Shore SA: Macrophage inflammatory protein-2 levels are associated with changes in serum leptin concentration following wore-induced airway inflammation. Chest. 2003;123(3 Suppl):369S-370S.
5. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Fazia M, Falco A, Cuccurullo F, Davi G: Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 2002;106:399-402.
6. Yehualaeshet T, O'Connor R, Begleiter A, Murphy-Ullrich JE, Silverstein R, Khalil N: A CD36 synthetic peptide inhibits bleomycin-induced pulmonary inflammation and connective tissue synthesis in the rat. Am J Respir Cell Mol Biol. 2000;23:204-212.
7. Adawi A, Zhang Y, Baggs R, Rubin P, Williams J, Finkelstein J, Phipps RP: Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. Clin Immunol Immunopathol. 1998;9:222-230.
8. Inselman LS, Chander A, Spitzer AR: Diminished lung compliance and elevated surfactant lipids and proteins in nutritionally obese young rats. Lung. 2004;182:101-117.
9. Lian XM, Yan C, Yang L, Xu Y, Du H: Lysosomal acid lipase deficiency causes respiratory inflammation and destruction in the lung. Am J Physiol Lung Cell Mol Physiol. 2004;286:801-807.
10. Du XG, Wang Q, Tang MX: Pathohistology observation in rat model of pulmonary atherosclerosis. J Yunyang Med School. 1997;16:120-123.
11. Owens GK, Kumar MS, Wamhoff BR: Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801.
12. Lopez-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA, Thompson RW: Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol. 1997;150:993-1007.
13. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN: Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med. 2002;166:1403-1408.
14. Fouty BW, Rodman DM: Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27Kip1-independent pathway. Circ Res. 2003;92:501-509.
15. Girgis RE, Mozammel S, Champion HC, Li D, Peng X, Shimoda L, Tuder RM, Johns RA, Hassoun PM: Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1105-L1110.
16. Pan DZ, Li YC: The effect of atorvastatin on hypoxia-induced pulmonary vascular remodeling in rat. China Gen Med. 2005;14:1149-1151.
17. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM: Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47:2554-2560.
18. Soyseth V, Brekke PH, Smith P, Omland T: Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29:279-283.
19. Frost FJ, Petersen H, Tollestrup K, Skipper B: Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131:1006-1012.
20. Everett AD, Le Cras TD, Xue C, Johns RA: eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow. Am J Physiol. 1998;274:L1058-L1065.
21. Gilliland FD, Berhane K, Islam T, McConnell R, Gauderman WJ, Gilliland SS, Avol E, Peters JM: Obesity and the risk of newly diagnosed asthma in school-age children. Am J Epidemiol. 2003;158:406-415.
22. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM: Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549-1555.
23. Huang Y, Chen YZ, Wang ZB: The effects of oxidized lipoprotein on expressions of NF-κB and PPARs in vascular endothelial cell and macrophage. J Chongqing Univ Med. 2003;28:576-579.
24. Nichols TC, Fischer TH, Deliargyris EN, Baldwin AS Jr: Role of nuclear factor-kappa B (NF-kappa B) in inflammation, periodontitis, and atherogenesis. Ann Periodontol. 2001;6:20-29.
25. Flohe L, Brigelius-Flohe R, Saliou C, Traber MG, Packer L: Redox regulation of NF-kappa B activation. Free Radic Biol Med. 1997;22:1115-1126.
26. May MJ, Ghosh S: Signal transduction through NF-kappa B. Immunol Today. 1998;19:80-88.
27. Bouloumie A, Marumo T, Lafontan M, Busse R: Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999;13:1231-1238.
28. Aderka D, Maor Y, Novick D, Engelmann H, Kahn Y, Levo Y, Wallach D, Revel M: Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. Blood. 1993;81:2076-2084.
29. Barton BE, Shortall J, Jackson JV: Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun. 1996;64:714-718.
30. Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA: Role of nuclear factor-kappa B in atherogenesis. Exp Physiol. 1997;82:297-304.
31. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995;92:3893-3897.
32. Xu QB, Oberhuber G, Gruschwitz M, Wick G: Immunology of atherosclerosis: cellular composition and major histocompat-ibility complex class II antigen expression in aortic intima, fatty streaks, and atherosclerotic plaques in young and aged human specimens. Clin Immunol Immunopathol. 1990;56:344-359.
33. Ludewig B, Freigan S, Jaggi M, et al.: Linking immunemediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci U S A. 2000;97:12752-12757.
34. Terkeltaub R, Boisvert WA, Curtiss, LK: Chemokines and atherosclerosis. Curr Opin Lipidol. 1998;9:397-405.
35. Li ZQ, Liu BW, Wei YW: Effect of OxLDL on cell cycling phases and PCNA, P53, P27 and cerbB expression in cultrued human arterialsmooth muscle cells. J West China Univ Med Sci. 1998;29:394-398.
36. Hayashi K, Takahashi M, Nishida W, et al.: Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ Res. 2001;89:251-258.
37. Wu XL, Wang SW, Yang ZS, et al.: The effect of oxidized low density lipoprotein on rabbit vascular smooth muscle cell biological function and the pharmacological mechanism of atorvastatin. Acad J PLA Postgrad Med School. 2002;23:245-247.
38. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG: Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691-696.
39. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446-1452.
40. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
41. Takai Y, Sasaki T, Matozaki T: Small GTP-binding proteins. Physiol Rev. 2001;81:153-208.
42. Wu SJ, Duan S, Zhao SP, et al.: Atorvastatin reduces lipopolysaccharide- induced expression of cyclooxygenase-2 in human pulmonary epithelial cells. Respir Res. 2005;6:27-32.
43. Wu SJ, Zhao SP: Effects of atorvastatin on lipopolysaccharide-induced expression of PGE2 and IL-6 in human pulmonary epithelial cells. J Central South Univ (Med Sci). 2004;29;192-194.
44. Kothe H, Dalhoff K, Rupp J, et al.: Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation. 2000;101:1760-1763.
45. Dichtl W, Dulak J, Frick M, et al.: HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:58-63.
46. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999;274:21926-21931.